Protein tyrosine phosphatase nonreceptor type 22 gene polymorphism in alopecia areata: Does it have an association with disease severity?
SALT score
alopecia areata
polymerase chain reaction-restriction fragment length polymorphism
protein tyrosine phosphatase nonreceptor type 22
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
13
12
2019
revised:
14
03
2020
accepted:
20
03
2020
pubmed:
14
4
2020
medline:
15
5
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Alopecia areata is a condition involving hair loss from certain or all areas of the body. It has been considered as an immune-mediated disease, characterized by the infiltration of CD4+ and CD8+ lymphocytes in the hair follicles. The study aimed to assess whether protein tyrosine phosphatase nonreceptor type 22 gene single nucleotide polymorphism 1858C/T has any relationship with alopecia areata in Egyptian patients and whether it is associated with disease severity or not. Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) C1858T gene polymorphism was identified using polymerase chain reaction-restriction fragment length polymorphism analysis technique in 60 patients suffering from alopecia areata and 30 age- and sex-matched healthy controls. Disease severity was assessed using SALT score. CT and TT genotypes were significantly higher in the patients' group (P = .005), OR = 4.38 95% CI [1.48-12.96], with significant statistical predominance of T allele in patients, P = .003, OR = 3.86, 95% CI [1.52-9.77]. There was also a positive significant relationship between protein tyrosine phosphatase nonreceptor type 22 genotype CT and SALT score. PTPN22 1858T allele is associated with the development and severity of alopecia areata in Egyptians.
Sections du résumé
BACKGROUND
BACKGROUND
Alopecia areata is a condition involving hair loss from certain or all areas of the body. It has been considered as an immune-mediated disease, characterized by the infiltration of CD4+ and CD8+ lymphocytes in the hair follicles.
AIM OF THE STUDY
OBJECTIVE
The study aimed to assess whether protein tyrosine phosphatase nonreceptor type 22 gene single nucleotide polymorphism 1858C/T has any relationship with alopecia areata in Egyptian patients and whether it is associated with disease severity or not.
SUBJECTS AND METHODS
METHODS
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) C1858T gene polymorphism was identified using polymerase chain reaction-restriction fragment length polymorphism analysis technique in 60 patients suffering from alopecia areata and 30 age- and sex-matched healthy controls. Disease severity was assessed using SALT score.
RESULTS
RESULTS
CT and TT genotypes were significantly higher in the patients' group (P = .005), OR = 4.38 95% CI [1.48-12.96], with significant statistical predominance of T allele in patients, P = .003, OR = 3.86, 95% CI [1.52-9.77]. There was also a positive significant relationship between protein tyrosine phosphatase nonreceptor type 22 genotype CT and SALT score.
CONCLUSION
CONCLUSIONS
PTPN22 1858T allele is associated with the development and severity of alopecia areata in Egyptians.
Substances chimiques
PTPN22 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 22
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3138-3144Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515-1525.
Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4(4):107-115.
McElwee KJ, Gilhar A, Tobin DJ, et al. What causes alopecia areata? Exp Dermatol. 2013;22(9):609-626.
Alkhalifah A, Alsantali A, Wang E, Mcelwee KJ, Shapiro J. Alopecia areata update (Part I). J Am Acad Dermatol. 2010;62:177-188.
Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP. Why is PTPN22 a good candidate susceptibility gene for auto-immune disease? FEBS Lett. 2011;585:3689-3698.
Maine CJ, Hamilton-Williams EE, Cheung J, et al. PTPN22 alters the development of regulatory T cells in the thymus. J Immunol. 2012;188:5267-5275.
Kavak A, Baykal C, Ozarmagan G, Akar U. HLA in alopecia areata. Int J Dermatol. 2000;39:589-592.
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines (Part II). J Am Acad Dermatol. 2004;51:440-447.
Kemp EH, McDonagh AJ, Wengraf DA, et al. The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata. Hum Immunol. 2006;67:535-539.
El-Zawahry BM, Azzam OA, Zaki NS, Abdel-Raheem HM, Bassiouny DA, Khorshied MM. PTPN22 gene polymorphism in Egyptian alopecia areata patients and its impact on response to diphencyprone immunotherapy. Gene. 2013;523:147-151.
Aljarousha M, Badarudin NE, Azemin MZ. Comparison of dry eye parameters between diabetics and non-diabetics in district of Kuantan, Pahang. Malays J Med Sci: MJMS. 2016;23(3):72.
Tabatabaei-Panah PS, Moravvej H, Arian S, et al. Overlapping and distinct FAS/FASLG gene polymorphisms in alopecia areata in an Iranian population. J Mol Cell Immunol. 2019;49:204-214.
Michou L, Lasbleiz S, Rat AC, et al. European consortium on rheumatoid arthritis families. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci USA. 2007;104:1649-1654.
Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific inducible human protein tyrosine phosphatase. Blood. 1999;93:2013-2014.
Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337-338.
Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes. 2004;53:3020-3023.
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Bukner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 2007;179:4704-4710.
Betz RC, Konig K, Flaquer A, et al. The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. Br J Dermatol. 2008;158:389-391.
Salinas-Santander M, Sánchez-Domínguez C, Cantú-Salinas C, et al. Association between PTPN22 C1858T polymorphism and alopecia areata risk. Exp Ther Med. 2015;10:1953-1958.
Bhanusali DG, Sachdev A, Olson MA, Gerlach JA, Sinha AA PTPN22 profile indicates a novel risk group in Alopecia areata. Hum Immunol. 2014;75:81-87.